Streptococcus agalactiae genome sequence, use for developing vaccines, diagnostic tools, and for identifying therapeutic targets

The invention concerns the genome sequence and nucleotide sequences coding for Streptococcus agalactiae polypeptides, such as cellular envelope polypeptides, or secreted or specific polypeptides, or polypeptides involved in the metabolism and the replication process, as well as vectors or cells comp...

Full description

Saved in:
Bibliographic Details
Main Authors CLAIRE POYART, PHILIPPE GLASER, CARMEN BUCHRIESER, MOHAMED ZOUINE, FRANK KUNST, PATRICK TRIEU-CUOT, CHRISTOPHE RUSNIOK, FABIEN CHEVALIER, LIONEL FRANGEUL, ELISABETH COUVE, LILA LALIOUI
Format Patent
LanguageEnglish
Published 25.11.2002
Edition7
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The invention concerns the genome sequence and nucleotide sequences coding for Streptococcus agalactiae polypeptides, such as cellular envelope polypeptides, or secreted or specific polypeptides, or polypeptides involved in the metabolism and the replication process, as well as vectors or cells comprising said sequences. The invention also concerns the use thereof for developing vaccines, diagnostic tools, DNA chips and for identifying therapeutic targets.
Bibliography:Application Number: AU20020319867